Results 21 to 30 of about 1,252,849 (358)

Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated guidelines and recommendations from the EBMT Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of EBMT and ISCT (JACIE)

Bone Marrow Transplantation, 2019
These updated EBMT guidelines review the clinical evidence, registry activity and mechanisms of action of haematopoietic stem cell transplantation (HSCT) in multiple sclerosis (MS) and other immune-mediated neurological diseases and provide ...
B. Sharrack, R. Saccardi, T. Alexander, M. Badoglio, J. Burman, D. Farge, R. Greco, H. Jessop, M. Kazmi, K. Kirgizov, M. Labopin, G. Mancardi, R. Martin, J. Moore, P. Muraro, M. Rovira, M. Sormani, J. Snowden, John Riccardo Eoin Franco Fermín Nina John Tobias Manue Snowden Saccardi McGrath Bambi Sanchez-Guijo Worel, J. Snowden, R. Saccardi, E. McGrath, F. Bambi, F. Sanchez-Guijo, N. Worel, Manuela Badolglio, M. Abinun, R. Arnold, C. Brierley, J. Burman, C. Castilla-Llorente, N. Cooper, T. Daikeler, N. Del Papa, D. Farge, J. Finke, H. Hagglund, J. Henes, F. Hiepe, D. Kiely, Z. Marjanovic, R. Martin, T. Martin, D. Ma, Paul Miller, P. Muraro, M. Oliveira, A. Polushin, F. Onida, B. Simões, M. Puyade, I. Resnick, M. Saif, I. Sakellari, E. Snarski, H. Scherer, C. Sossa, Jeska K De Vries-Bouwstra, N. Wulffraat, E. Zaccara   +59 more
semanticscholar   +1 more source

Hematopoietic progenitor cell content of vertebral body marrow used for combined solid organ and bone marrow transplantation [PDF]

, 1995
While cadaveric vertebral bodies (VB) have long been proposed as a suitable source of bone marrow (BM) for transplantation (BMT), they have rarely been used for this purpose. We have infused VB BM immediately following whole organ (WO) transplantation to
Ball, ED, Fontes, PA, Rao, AS, Ricordi, C, Rybka, WB, Starzl, TE, Winkelstein, A   +6 more
core   +1 more source

Current status of autologous stem cell transplantation for multiple myeloma

Blood Cancer Journal, 2019
More than 30 years after its introduction, autologous stem cell transplantation (ASCT) remains the standard of care for young patients with newly diagnosed multiple myeloma. Not only did the arrival of novel agents such as immunomodulatory drugs (IMiDs),
Rama Al Hamed, A. Bazarbachi, F. Malard, J. Harousseau, M. Mohty   +4 more
semanticscholar   +1 more source

Limbal stem cell transplantation: clinical results, limits, and perspectives [PDF]

, 2018
Limbal stem cell deficiency (LSCD) is a clinical condition characterized by damage of cornea limbal stem cells, which results in an impairment of corneal epithelium turnover and in an invasion of the cornea by the conjunctival epithelium.
Bruscolini, Alice, Lambiase, Alessandro, Rama, Paolo, Sacchetti, Marta   +3 more
core   +1 more source

Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplantation in multiple myeloma.

Blood, 2019
Achieving and maintaining high-quality response is the treatment goal for patients with newly diagnosed multiple myeloma (NDMM). The phase 3 PETHEMA/GEM2012 study, in 458 patients {less than or equal to} 65 years old with NDMM, is evaluating bortezomib ...
L. Rosiñol, A. Oriol, R. Ríos, A. Sureda, M. Blanchard, M. Hernandez, R. Martínez-Martínez, J. Moraleda, I. Jarque, J. Bargay, M. Gironella, F. de Arriba, L. Palomera, Y. Gonzalez-Montes, J. Martí, I. Krsnik, J. Arguiñano, Maria-Esther Gonzalez, A. Gonzalez, L. Casado, L. López-Anglada, B. Paiva, M. Mateos, J. S. San Miguel, J. Lahuerta, J. Bladé   +25 more
semanticscholar   +1 more source

Multiple Myeloma Patients at Various Cytogenetic Risks Benefit Differently from Autologous Stem Cell Transplantation as a Consolidation Therapy

Stem Cells International, 2015
Aim. To evaluate whether patients with multiple myeloma at various risks can still benefit the same from autologous stem cell transplantation consolidation in the era of novel agents.
Tianmei Zeng, Lili Zhou, Hao Xi, Weijun Fu, Juan Du, Chunyang Zhang, Hua Jiang, Jian Hou   +7 more
doaj   +1 more source

Quality of Life and psychopathology in adults who underwent Hematopoietic Stem Cell Transplantation (HSCT) in childhood: a qualitative and quantitative analysis. [PDF]

, 2017
Background: Patients who undergo pediatric Hematopoietic Stem Cell Transplantation (HSCT) may experience long-term psychological sequelae and poor Quality of Life (QoL) in adulthood. This study aimed to investigate subjective illness experience, QoL, and
Basso, G., Boscolo, Valentina, Calore, E., Cattelan, C., Di Florio, N., Mainardi, C., Marzollo, A., Messina, C., Pillon, M., Porreca, A., Sinatora, F., Traverso, A., Tremolada, M., Zanato, S.   +13 more
core   +2 more sources

The role of autologous stem cell transplantation in patients with nodal peripheral T‐cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study

Cancer, 2019
The role of autologous stem cell transplantation (ASCT) in the first complete remission (CR1) of peripheral T‐cell lymphomas (PTCLs) is not well defined.
Steven I. Park, S. Horwitz, F. Foss, L. Pinter-Brown, K. Carson, S. Rosen, B. Pro, E. Hsi, M. Federico, C. Gisselbrecht, M. Schwartz, L. Bellm, M. Acosta, R. Advani, T. Feldman, M. Lechowicz, Sonali M. Smith, F. Lansigan, A. Tulpule, M. Craig, J. Greer, B. Kahl, J. Leach, N. Morganstein, C. Casulo, A. Shustov   +25 more
semanticscholar   +1 more source

Autoimmunity in Autologous Islet Transplantation

OBM Transplantation, 2018
Total pancreatectomy (TP) is increasingly being utilized for definitive treatment in patients with debilitating chronic pancreatitis (CP). In an effort to prevent surgical diabetes, the procedure can be performed in conjunction with transplantation of islets of Langerhans recovered from the patients' own resected pancreas (autologous islet ...
R. Matthew Walsh, Khawla F. Ali, Rita Bottino, Betul Hatipoglu, Tyler Stevens, Vicente T San Martin, Massimo Trucco   +6 more
openaire   +3 more sources

Lovo‐cel gene therapy for sickle cell disease: Treatment process evolution and outcomes in the initial groups of the HGB‐206 study

American Journal of Hematology, Volume 98, Issue 1, Page 11-22, January 2023., 2023
Treatment process evolution. *The target TNC for BMH was ≥6 × 108/kg per patient. The Group B1 patient received lovo‐cel produced using both the original and refined manufacturing process, and the Group B2 patient received lovo‐cel produced using only the refined manufacturing process.
Julie Kanter, Alexis A. Thompson, Francis J. Pierciey Jr, Matthew Hsieh, Naoya Uchida, Philippe Leboulch, Manfred Schmidt, Melissa Bonner, Ruiting Guo, Alex Miller, Jean‐Antoine Ribeil, David Davidson, Mohammed Asmal, Mark C. Walters, John F. Tisdale   +14 more
wiley   +1 more source